Emmaus Life Sciences Inc

OTCQX US:EMMAUnited States

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery, development, marketing, and sale of treatments and therapies, primarily for rare and orphan diseases. The Company’s lead product, Endari (prescription-grade L-glutamine oral powder), helps to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients aged five years and older. Its product pipeline includes ELS001/ELS007, ELS004, ELS005, ELS003, and ELS002. The Company, through Kainos Medicine, Inc. (Kainos), has a license in the territory encompassing the United States, the United Kingdom, and the European Union to patent rights, know-how, and other intellectual property relating to Kainos’s IRAK4 inhibitor, referred to as KM10544, for the treatment of cancers, including leukemia, lymphoma, and solid tumor cancers. It has also developed chondrocyte and osteoblast cell sheets using human mesenchymal stem cells.

Contact Information

Headquarters

21250 HAWTHORNE BOULEVARD, SUITE 800TORRANCE, CA, United States 90503

Phone

310-214-0065

Fax

310-214-0075

Executives

Chairman of the Board, Co-President, Chief Operating Officer, Executive Director

Willis Lee

Co-President, Senior Vice President - Global Commercialization, Chief Information Officer, Director

George Sekulich

Chief Financial Officer

Yasushi Nagasaki

Senior Vice President - Medical Affairs, Clinical, Regulatory

Charles Stark

Independent Director

Seah Lim